Shahram Paydar: TXA in Elderly Trauma: A Game-Changer for Endothelial Protection?
Shahram Paydar, Professor of Surgery and Trauma Surgeon, Consultant at Gulf Specialized Hospital, shared on LinkedIn:
“TXA in Elderly Trauma: A Game-Changer for Endothelial Protection? New Evidence Says Yes!
Trauma doesn’t discriminate by age, but outcomes do—especially for our older adults, who make up nearly 25% of admissions yet face steeper morbidity and mortality. Enter tranexamic acid (TXA): We know it’s a staple for bleeding control in TBI and hemorrhage, but a fresh 2025 analysis in J Trauma Acute Care Surg spotlights its extra punch in the ≥55 crowd.
Key findings from this secondary dive into the prehospital TXA-in-TBI database (n=436):
Despite similar injury severity (ISS ~20, head AIS ~3), older patients (mean 66y) showed sky-high admission endothelial biomarkers—thrombomodulin (↑17%), VCAM-1 (↑19%), angiotensin-2 (↑23%)—signaling pre-injury vulnerability.
The kicker?
2g prehospital TXA dampened these markers more dramatically in elders vs. younger folks (e.g., thrombomodulin p<0.00001, VCAM-1 p<0.0002 vs. placebo).
Younger subsets?
Less impact.
Why does this matter?
Endothelial dysfunction fuels the post-trauma inflammatory storm, and elders start from a weaker baseline. TXA’s amplified endothelial “shield” here could blunt hypercoagulability, reduce secondary hits, and—potentially—tip the scales on survival and recovery.
No direct mortality links yet (Level IV evidence), but it’s a clarion call: Standard TXA protocols might pack bigger benefits for our aging trauma wave.
As populations gray, this underscores TXA’s role beyond hemostasis—it’s endothelial insurance for the vulnerable.
Time to tweak protocols? Or wait for RCTs?
What’s your take—ramping up TXA emphasis in elder polytrauma? Share protocols or cases below!”
Title: Age matters: A Secondary Analysis of Endothelial Biomarkers in the Prehospital Tranexamic Acid for Traumatic Brain Injury Trial
Authors: Tanya Anand, Scott McLoud, Lindsay Loss, Karen Minoza, Phillip Jenkins, Susan Rowell, Jack McLean, Bellal Joseph, Martin Schreiber
Read the full article here.
Stay updated with Hemostasis Today.
-
Dec 16, 2025, 15:39Reza Shojaei: Every Expired Unit of Blood Tells a Story
-
Dec 16, 2025, 14:03Francesco Lo Monaco on Rethinking Blood Pressure: The Major Problem with How We Understand It
-
Dec 16, 2025, 14:03Marilena Vrana Urges EU Policymakers to “Keep Patients at the Centre” of Critical Medicines Act
-
Dec 16, 2025, 14:02Even Distribution of Protective Hemoglobin Prevents Sickle Cell Symptoms
-
Dec 16, 2025, 13:58AHA Awards Shubham Misra Postdoc Grant for LVO Stroke Biomarker Research
-
Dec 16, 2025, 13:00ScholarGPS Ranks Emmanuel J. Favaloro No. 1 in the World for Hemostasis
-
Dec 16, 2025, 11:30Kingsley Wheaton: Sweden is on the Brink of Becoming the World’s 1st Smoke-Free Country
-
Dec 16, 2025, 11:03Matías J Alet on CABOS Project with The Support of WSO
-
Dec 16, 2025, 00:32New on EHCucate: Read about the “History of Replacement Factor Therapies” and More